Sionna Therapeutics (SION) Net Cash Flow (2024 - 2026)

Sionna Therapeutics has disclosed Net Cash Flow across 3 years of filings, most recently posting $4.9 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $4.9 million, down 89.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.4 million (down 33882.46% YoY), and the FY2025 annual result was $20.7 million, up 2919.1% from the prior year.
• Net Cash Flow came in at $4.9 million for Q1 2026 at Sionna Therapeutics, down from $7.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $44.9 million in Q1 2025 to a low of -$41.7 million in Q2 2025.
• The 3-year median for Net Cash Flow is $4.9 million (2026), against an average of $2.8 million.
• Across the five-year window, Net Cash Flow jumped 273.76% in 2025 and sank 89.15% in 2026, its largest moves.
• Sionna Therapeutics' Net Cash Flow stood at $2.0 million in 2024, then surged by 273.76% to $7.6 million in 2025, then slumped by 36.06% to $4.9 million in 2026.
• The last three Net Cash Flow figures came in at $4.9 million (Q1 2026), $7.6 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.